This company listing is no longer active
Biofrontera Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 3/6
Wichtige Informationen
32.4%
Wachstumsrate der Gewinne
41.1%
EPS-Wachstumsrate
| Pharmaceuticals Wachstum der Industrie | 7.3% |
| Wachstumsrate der Einnahmen | 17.6% |
| Eigenkapitalrendite | 28.1% |
| Netto-Marge | 33.9% |
| Letzte Ertragsaktualisierung | 30 Jun 2022 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Aufschlüsselung der Einnahmen und Ausgaben
Wie Biofrontera Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 22 | 31 | 10 | 24 | 7 |
| 31 Mar 22 | 30 | 15 | 29 | 7 |
| 31 Dec 21 | 29 | 38 | 34 | 7 |
| 30 Sep 21 | 28 | -16 | 28 | 6 |
| 30 Jun 21 | 27 | -16 | 29 | 5 |
| 31 Mar 21 | 29 | -12 | 26 | 5 |
| 31 Dec 20 | 30 | -13 | 28 | 5 |
| 30 Sep 20 | 33 | -17 | 33 | 5 |
| 30 Jun 20 | 33 | -22 | 37 | 5 |
| 31 Mar 20 | 31 | -10 | 45 | 5 |
| 31 Dec 19 | 31 | -7 | 44 | 5 |
| 30 Sep 19 | 26 | 1 | 44 | 4 |
| 30 Jun 19 | 26 | 8 | 40 | 5 |
| 31 Mar 19 | 23 | -8 | 33 | 5 |
| 31 Dec 18 | 21 | -9 | 31 | 4 |
| 30 Sep 18 | 19 | -14 | 24 | 4 |
| 30 Jun 18 | 16 | -15 | 22 | 4 |
| 31 Mar 18 | 14 | -16 | 21 | 4 |
| 31 Dec 17 | 12 | -16 | 20 | 4 |
| 30 Sep 17 | 11 | -18 | 21 | 5 |
| 30 Jun 17 | 9 | -16 | 17 | 5 |
| 31 Mar 17 | 8 | -14 | 14 | 5 |
| 31 Dec 16 | 6 | -11 | 12 | 5 |
| 30 Sep 16 | 4 | -9 | 9 | 4 |
| 30 Jun 16 | 4 | -7 | 8 | 4 |
| 31 Mar 16 | 4 | -9 | 7 | 6 |
| 31 Dec 15 | 4 | -11 | 7 | 6 |
| 30 Sep 15 | 4 | -12 | 7 | 7 |
Qualität der Erträge: B8FE has a large one-off gain of €39.7M impacting its June 30 2022 financial results.
Wachsende Gewinnspanne: B8FE became profitable in the past.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: B8FE has become profitable over the past 5 years, growing earnings by 32.4% per year.
Beschleunigtes Wachstum: B8FE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Erträge im Vergleich zur Industrie: B8FE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.2%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: B8FE's Return on Equity (28.1%) is considered high.